

LIST OF FIGURES

| | | Page No. |
|-----------|--|-----------------|
| Fig. 2.1 | Schematic of nasal drug delivery | 8 |
| Fig. 2.2 | Schematic of a sagittal section of human nasal cavity | 11 |
| Fig. 2.3 | Cell types of the nasal epithelium | 12 |
| Fig. 2.4 | Schematic representation of transport routes across nasal respiratory epithelium | 20 |
| Fig. 2.5 | The physicochemical, anatomical, physiological and formulation factors affecting the nasal absorption of drugs | 21 |
| Fig. 3.1 | Standard Curve of Carvedilol in pH 6.2 phosphate buffer and methanol (9:1) | 70 |
| Fig. 3.2 | Standard Curve of Carvedilol in methanol and 0.1N HCl (3:2) | 73 |
| Fig. 3.3 | Standard Curve of Nitrendipine in pH 6.2 phosphate buffer containing 1% Tween 80 | 77 |
| Fig. 3.4 | Standard Curve of Nitrendipine in methanol and 0.1N HCl (3:2) | 80 |
| Fig. 4.1 | Effect of chitosan concentration on particle size of microspheres | 94 |
| Fig. 4.2 | Effect of aqueous to oil phase on particle size of microspheres | 95 |
| Fig. 4.3 | Effect of stirring rate on particle size of microspheres | 96 |
| Fig. 4.4 | Photomicrograph of CRV loaded chitosan microspheres | 99 |
| Fig. 4.5 | SEM photograph of CRV loaded chitosan microspheres | 99 |
| Fig. 4.6 | Adsorption of mucin on different microspheres with respect to the amount of mucin added | 101 |
| Fig. 4.7A | Freundlich adsorption isotherms for mucin adsorbed on chitosan microspheres (Batches CHCR1 to CHCR4) | 102 |
| Fig. 4.7B | Freundlich adsorption isotherms for mucin adsorbed on chitosan microspheres (Batches CHCR5 to CHCR8) | 102 |
| Fig. 4.8A | Langmuir adsorption isotherms of mucin adsorbed on chitosan microspheres (Batches CHCR1 to CHCR4) | 103 |
| Fig. 4.8B | Langmuir adsorption isotherms of mucin adsorbed on | 103 |

| | | |
|------------|--|-----|
| | chitosan microspheres (Batches CHCR1 to CHCR4) | |
| Fig. 4.9 | Percentage <i>in vitro</i> mucoadhesion for different batches of microspheres | 105 |
| Fig. 4.10A | <i>In vitro</i> drug release profile of chitosan microspheres of CRV (Batches CHCR1 to CHCR4). | 106 |
| Fig. 4.10B | <i>In vitro</i> drug release profile of chitosan microspheres of CRV (Batches CHCR5 to CHCR8). | 106 |
| Fig. 4.11 | DSC thermograms of (A) pure carvedilol; (B) drug loaded microspheres; and (C) placebo microspheres | 110 |
| Fig. 4.12 | DSC thermograms of (A) pure carvedilol; (B) drug loaded microspheres; and (C) placebo microspheres | 111 |
| Fig. 4.13 | Histology evaluations of sections of sheep nasal mucosa | 112 |
| Fig. 5.1 | SEM Photograph of placebo alginate microspheres | 123 |
| Fig. 5.2 | SEM Photograph of CRV loaded alginate microspheres | 123 |
| Fig. 5.3 | Percentage <i>in vitro</i> mucoadhesion for different batches of microspheres | 125 |
| Fig. 5.4 | DSC thermograms of (A) pure carvedilol; (B) placebo microspheres; (C) drug loaded microspheres | 126 |
| Fig. 5.5 | Powder X-ray diffraction patterns of (A) pure carvedilol; (B) placebo microspheres; (C) drug loaded microspheres | 127 |
| Fig. 5.6 | <i>In vitro</i> drug release profile of alginate microspheres of CRV (Batches ALCR1 to ALCR4) | 128 |
| Fig. 5.7 | <i>In vitro</i> drug release profile of alginate microspheres of CRV (Batches ALCR5 to ALCR8) | 129 |
| Fig. 5.8 | Response surface plots for the (a) effects of drug: polymer ratio (X1) and CaCl ₂ concentration (X2) on particle size (Y1). | 134 |
| Fig. 5.9 | Response surface plots for the effects of CaCl ₂ concentration (X2) and cross linking time (X3) on particle size (Y1) | 134 |
| Fig. 5.10 | Response surface plots for the effects of drug: polymer ratio (X1) and cross linking time (X3) on particle size (Y1) | 135 |
| Fig. 5.11 | Contour plots for the effects of drug: polymer ratio (X1) and CaCl ₂ concentration (X2) on particle size (Y1) | 135 |

| | | |
|-----------|---|-----|
| Fig. 5.12 | Contour plots for the effects of CaCl ₂ concentration (X2) and cross linking time (X3) on particle size (Y1) | 136 |
| Fig. 5.13 | Contour plots for the effects of drug: polymer ratio (X1) and cross linking time (X3) on particle size (Y1) | 136 |
| Fig. 5.14 | Response surface plots for the effects of drug: polymer ratio (X1) and CaCl ₂ concentration (X2) on in vitro mucoadhesion (Y2) | 137 |
| Fig. 5.15 | Response surface plots for the effects of CaCl ₂ concentration (X2) and cross linking time (X3) on in vitro mucoadhesion (Y2) | 138 |
| Fig. 5.16 | Response surface plots for the effects of drug: polymer ratio (X1) and cross linking time (X3) on in vitro mucoadhesion (Y2) | 138 |
| Fig. 5.17 | Contour plots for the effects of drug: polymer ratio (X1) and CaCl ₂ concentration (X2) on in vitro mucoadhesion (Y2). | 139 |
| Fig. 5.18 | Contour plots for the effects of CaCl ₂ concentration (X2) and cross linking time (X3) on in vitro mucoadhesion (Y2) | 139 |
| Fig. 5.19 | Contour plots for the effects of drug: polymer ratio (X1) and cross linking time (X3) on in vitro mucoadhesion (Y2) | 140 |
| Fig. 5.20 | Correlation between actual and predicted values for particle size | 142 |
| Fig. 5.21 | Correlation between actual and predicted values for in vitro mucoadhesion | 142 |
| Fig. 5.22 | Histology evaluations of sections of sheep nasal mucosa | 144 |
| Fig. 6.1 | Photomicrograph of NTD loaded chitosan microspheres | 153 |
| Fig. 6.2 | SEM photograph of NTD loaded chitosan microspheres | 153 |
| Fig. 6.3 | Cross linking process of chitosan treated with glutaraldehyde | 154 |
| Fig. 6.4 | Adsorption of mucin on different microspheres with respect to the amount of mucin added | 156 |
| Fig. 6.5A | Freundlich adsorption isotherms for mucin adsorbed on chitosan microspheres (Batches CHCR1 to CHCR4) | 157 |
| Fig. 6.5B | Freundlich adsorption isotherms for mucin adsorbed on chitosan microspheres (Batches CHCR5 to CHCR8) | 157 |

| | | |
|-----------|---|-----|
| Fig. 6.6A | Langmuir adsorption isotherms of mucin adsorbed on chitosan microspheres (Batches CHCR1 to CHCR4) | 158 |
| Fig. 6.6B | Langmuir adsorption isotherms of mucin adsorbed on chitosan microspheres (Batches CHCR5 to CHCR8) | 158 |
| Fig. 6.7 | Percentage in vitro mucoadhesion for different batches of microspheres | 160 |
| Fig. 6.8A | <i>In vitro</i> drug release profile of chitosan microspheres of NTD (Batches CHNT1 to CHNT4) | 161 |
| Fig. 6.8B | <i>In vitro</i> drug release profile of chitosan microspheres of NTD (Batches CHNT5 to CHNT8) | 161 |
| Fig. 6.9 | DSC thermograms of (A) pure nitrendipine; (B) placebo microspheres; and (C) NTD loaded microspheres | 164 |
| Fig. 6.10 | Powder X-ray diffraction patterns of (A) pure nitrendipine; (B) placebo microspheres; and (C) nitrendipine loaded microspheres | 165 |
| Fig. 6.11 | Histology evaluations of sections of sheep nasal mucosa | 167 |
| Fig. 7.1 | The structure of alginate | 177 |
| Fig. 7.2 | SEM Photograph NTD loaded alginate microspheres at 2000X | 178 |
| Fig. 7.3 | SEM Photograph of NTD loaded alginate microspheres at 100X | 178 |
| Fig. 7.4 | Percentage in vitro mucoadhesion for different batches of microspheres | 180 |
| Fig. 7.5 | DSC thermograms of (A) pure NTD; (B) placebo microspheres; (C) drug loaded microspheres. | 181 |
| Fig. 7.6 | Powder X-ray diffraction patterns of (A) pure NTD; (B) placebo microspheres; (C) NTD loaded microspheres | 182 |
| Fig. 7.7 | <i>In vitro</i> drug release profile of alginate microspheres of NTD (Batches ALNT1 to ALNT4) | 183 |
| Fig. 7.8 | <i>In vitro</i> drug release profile of alginate microspheres of NTD (Batches ALNT5 to ALNT8) | 183 |
| Fig. 7.9 | Response surface plots for the (a) effects of drug: polymer ratio (X1) and CaCl ₂ concentration (X2) on particle size (Y1) | 188 |

| | | |
|-----------|---|-----|
| Fig. 7.10 | Response surface plots for the effects of CaCl ₂ concentration (X2) and cross linking time (X3) on particle size (Y1). | 188 |
| Fig. 7.11 | Response surface plots for the effects of drug: polymer ratio (X1) and cross linking time (X3) on particle size (Y1) | 189 |
| Fig. 7.12 | Contour plots for the effects of drug: polymer ratio (X1) and CaCl ₂ concentration (X2) on particle size (Y1) | 189 |
| Fig. 7.13 | Contour plots for the effects of CaCl ₂ concentration (X2) and cross linking time (X3) on particle size (Y1). | 190 |
| Fig. 7.14 | Contour plots for the effects of drug: polymer ratio (X1) and cross linking time (X3) on particle size (Y1). | 190 |
| Fig. 7.15 | Response surface plots for the effects of drug: polymer ratio (X1) and CaCl ₂ concentration (X2) on in vitro mucoadhesion (Y2) | 191 |
| Fig. 7.16 | Response surface plots for the effects of CaCl ₂ concentration (X2) and cross linking time (X3) on in vitro mucoadhesion (Y2) | 192 |
| Fig. 7.17 | Response surface plots for the effects of drug: polymer ratio (X1) and cross linking time (X3) on in vitro mucoadhesion (Y2) | 192 |
| Fig. 7.18 | Contour plots for the effects of drug: polymer ratio (X1) and CaCl ₂ concentration (X2) on in vitro mucoadhesion (Y2) | 193 |
| Fig. 7.19 | Contour plots for the effects of CaCl ₂ concentration (X2) and cross linking time (X3) on in vitro mucoadhesion (Y2) | 193 |
| Fig. 7.20 | Contour plots for the effects of drug: polymer ratio (X1) and cross linking time (X3) on in vitro mucoadhesion (Y2) | 194 |
| Fig. 7.21 | Correlation between actual and predicted values for particle size | 196 |
| Fig. 7.22 | Correlation between actual and predicted values for in vitro mucoadhesion | 196 |
| Fig. 7.23 | Histology evaluations of sections of sheep nasal mucosa | 198 |
| Fig. 8.1 | MIAT [®] monodose nasal insufflator | 203 |
| Fig. 8.2 | The spray pattern (shape) of CRV loaded chitosan microspheres from MIAT [®] nasal monodose insufflator | 209 |

| | | |
|-----------|--|-----|
| Fig. 8.3 | The spray pattern (shape) of NTD loaded chitosan microspheres from MIAT [®] nasal monodose insufflator | 209 |
| Fig. 8.4 | The spray pattern (shape) of CRV loaded alginate microspheres from MIAT [®] nasal monodose insufflator | 210 |
| Fig. 8.5 | The spray pattern (shape) of NTD loaded alginate microspheres from MIAT [®] nasal monodose insufflator | 210 |
| Fig. 9.1 | Blood radioactivity time profiles of CRV after administration of microspheres intranasally (IN) (1 mg kg ⁻¹) and CRV solution intravenously (IV) (0.17 mg kg ⁻¹) in rabbits | 223 |
| Fig. 9.2 | The clearance characteristics of radiolabeled chitosan microspheres (CHCR) and alginate microspheres (ALCR) from the rabbit nasal cavity as compared to lactose powder a control | 227 |
| Fig. 9.3 | Scintigraphic rabbit whole body images showing radioactivity in the nasal cavity after administration of ^{99m} Tc labeled chitosan microspheres of carvedilol (CHCR) at different times of 0 h (A), 1 h (B), 2 h (C), 3 h (D) and 4 h (E) post insufflation | 229 |
| Fig. 9.4 | Scintigraphic rabbit whole body images showing radioactivity in the nasal cavity after administration of ^{99m} Tc labeled alginate microspheres of carvedilol (ALCR) at different times of 0 h (A), 1 h (B), 2 h (C), 3 h (D) and 4 h (E) post insufflation | 230 |
| Fig. 9.5 | Scintigraphic rabbit whole body images showing radioactivity in the nasal cavity after administration of ^{99m} Tc labeled lactose powder (control) at different times of 0 h (A), 1 h (B) and 2 h (C) post insufflation | 231 |
| Fig. 10.1 | Blood radioactivity time profiles of NTD after administration of microspheres intranasally (IN) (1.25 mg kg ⁻¹) and NTD solution intravenously (IV) (0.2 mg kg ⁻¹) in rabbits | 242 |
| Fig. 10.2 | The clearance characteristics of radiolabeled chitosan microspheres (CHNT) and alginate microspheres (ALNT) from the rabbit nasal cavity as compared to lactose powder a | 245 |

- control
- Fig. 10.3 Scintigraphic rabbit whole body images showing 247
radioactivity in the nasal cavity after administration of ^{99m}Tc
labeled chitosan microspheres of nitrendipine (CHNT) at
different times of 0 h (A), 1 h (B), 2 h (C), 3 h (D) and 4 h
(E) post insufflation
- Fig. 10.4 Scintigraphic rabbit whole body images showing 248
radioactivity in the nasal cavity after administration of ^{99m}Tc
labeled alginate microspheres of nitrendipine (ALNT) at
different times of 0 h (A), 1 h (B), 2 h (C), 3 h (D) and 4 h
(E) post insufflation
- Fig. 10.5 Scintigraphic rabbit whole body images showing 249
radioactivity in the nasal cavity after administration of ^{99m}Tc
labeled lactose powder (control) at different times of 0 h (A),
1 h (B) and 2 h (C) post insufflation